glucose, (beta-d)-isomer and Cardiovascular Diseases
glucose, (beta-d)-isomer has been researched along with Cardiovascular Diseases in 313 studies
Research
Studies (313)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (0.64) | 18.7374 |
1990's | 1 (0.32) | 18.2507 |
2000's | 2 (0.64) | 29.6817 |
2010's | 206 (65.81) | 24.3611 |
2020's | 102 (32.59) | 2.80 |
Authors
Authors | Studies |
---|---|
Johnston, TP; Korolenko, TA; Pirro, M; Sahebkar, A | 1 |
Caputi, AP; Cuzzocrea, S; Falciani, M; Filippelli, A; Rossi, F; Zingarelli, B | 1 |
Brueckmann, M; Butler, J; Fitchett, DH; George, JT; Inzucchi, SE; Mattheus, M; Ofstad, AP; Sattar, N; Vaduganathan, M; Verma, S; Wanner, C; Zinman, B | 1 |
Ferreira, JP; Inzucchi, SE; Mattheus, M; Meinicke, T; Steubl, D; Wanner, C; Zinman, B | 1 |
Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Glynn, RJ; Najafzadeh, M; Paik, JM; Patorno, E; Pawar, A; Schneeweiss, S; Wexler, DJ | 1 |
Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C | 1 |
Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V | 1 |
Anker, SD; Kaku, K; Lund, SS; Mattheus, M; Pocock, S; Wanner, C; Yasui, A | 1 |
Bhatt, DL; Gause-Nilsson, I; Kolkailah, AA; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
Chaitoff, A; Fischer, MA; Gong, J; Niforatos, JD | 1 |
Brandt, NH; Ersbøll, M; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B | 1 |
Bové, KB; Nilsson, M; Prescott, E; Suhrs, HE; Zander, M | 1 |
Inzucchi, SE; Kahl, S; Ofstad, AP; Roden, M; Sattar, N; Schüler, E; Wanner, C; Zinman, B | 1 |
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Moore, CM | 1 |
García, Á; Gil-Rojas, Y; Lasalvia, P | 1 |
Balasubramanian, P; Elsaesser, A; Ferreira, JP; Inzucchi, SE; Ofstad, AP; Wanner, C; Zinman, B | 1 |
Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B | 1 |
Chen, Y; Deng, X; Fang, Y; Kan, Q; Liu, Y; Man, H; Shang, J; Shi, X; Tang, S; Wang, D; Wang, L; Wang, P; Wei, W; Yang, H; Yang, J; Yuan, H; Yuan, Q; Zhang, C; Zhang, Y | 1 |
Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC | 1 |
Shao, G | 1 |
Dural, İE; Ersoy, İ; Sarı, A | 1 |
Hansmann, J; Lizio, R; Ockermann, P | 1 |
Huang, K; Liu, J; Sun, S; Wang, Y; Xie, X; Zhou, W; Zhu, D; Zhu, Q | 1 |
Barreto, J; Bonilha, I; Breder, I; Breder, J; Coelho, OR; Coelho-Filho, OR; de Carvalho, LSF; do Carmo, HR; Kimura-Medorima, ST; Lima, M; Luchiari, B; Matos-Souza, JR; Moura, FA; Munhoz, D; Nadruz, W; Oliveira, A; Oliveira, D; Quinaglia, T; Sposito, AC; Wolf, V | 1 |
Dixen, U; Fenger, M; Goetze, JP; Holst, JJ; Jørgensen, NB; Madsbad, S; Madsen, PL; Richter, EA; Thirumathyam, R; Van Hall, G; Vejlstrup, N | 1 |
Slomski, A | 2 |
Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA | 1 |
Doumas, M; Karagiannis, A; Katsimardou, A; Papadopoulos, C; Patoulias, D; Zografou, I | 1 |
Aleksandric, M; Fülöp, T; Gumprecht, J; Kamenov, Z; Medvedchikov, A; Prázný, M; Rosenzweig, D; Suplotova, L | 1 |
Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE | 1 |
Ageev, FT; Ametov, AS; Antsiferov, MB; Arutyunov, GP; Cherkashin, DV; Fomin, IV; Galstyan, GR; Galyavich, AS; Gilyarevskiy, SR; Glezer, MG; Ilyin, MV; Khalimov, IS; Khasanov, NR; Lebedeva, AI; Lopatin, YM; Nedogoda, SM; Salukhov, VV; Tarlovskaya, EI; Tereshchenko, SN; Villevalde, SV; Vinogradova, NG; Yakushin, SS; Zhirov, IV | 1 |
Catharina de Beer, J; Ker, J; Miller-Janson, H; Snyman, J; Stander, M | 1 |
Advani, A; Cherney, DZI; Dubrofsky, L; Kugathasan, L | 1 |
Bég, SA; Dar, MS; Kaspers, S; Marx, N; Mattheus, M; Ofstad, AP; Wanner, C | 1 |
Cauchon, M; Lanthier, L; Plourde, ME; Viau-Trudel, A | 1 |
Ding, Y; Liu, Y; Peng, Y; Wang, H; Wang, Y; Zhang, X; Zhang, Y | 1 |
Candido, R; Cucinotta, D; Graziano, G; Manicardi, V; Nicolucci, A; Rocca, A; Rossi, MC; Tuccinardi, F | 1 |
Avogaro, A; Bonora, BM; Fadini, GP; Vigili de Kreutzenberg, S | 1 |
Handelsman, Y | 2 |
Gippini, A; Prado, A | 1 |
Abraitienė, A; Ametov, AS; Gaàl, Z; Gumprecht, J; Janež, A; Karasik, A; Kaser, S; Lalić, K; Mankovsky, BN; Moshkovich, E; Past, M; Prázný, M; Radulian, G; Schernthaner, G; Smirčić Duvnjak, L; Tkáč, I; Trušinskis, K | 1 |
Al-Omran, M; Bhatt, DL; Connelly, KA; Dhingra, N; Hess, DA; Leiter, LA; Mason, T; Mazer, CD; Quan, A; Rotstein, OD; Sabongui, S; Teoh, H; Terenzi, DC; Trac, JZ; Verma, S; Yan, AT; Zinman, B | 1 |
Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Mattheus, M; Vedin, O; Wanner, C; Zinman, B | 1 |
Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
Chan, YY; Chang, KC; Chen, HY; Hung, MJ; Kao Yang, YH; Lai, EC; Shao, SC; Yang, NI | 1 |
Bergenstal, RM; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Kaspers, S; Kiš, SG; Monteiro, P; Toural, E; Zinman, B | 1 |
Moist, L | 2 |
Cahn, A; Cernea, S; Raz, I | 1 |
Brandt, NH; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, S; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wiberg, M; Wolsk, E; Zerahn, B | 1 |
Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Janista, C; Jurišić-Eržen, D; Kaspers, S; Woo, V; Zinman, B | 1 |
Canivell, S; Franch-Nadal, J; Gratacòs, M; Mata-Cases, M; Mauricio, D; Real, J; Vlacho, B | 1 |
Aguiar, C; Birne, R; Branco, P; Calado, J; Matos, P; Melo, M; Monteiro, P; Polónia, J; Silva-Nunes, J | 1 |
Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H | 1 |
Al-Bazz, DY; Wilding, JP | 1 |
Foresto, RD; Gonzalez, DE; Ribeiro, AB | 1 |
Masuda, D; Yamashita, S | 1 |
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC | 1 |
Chan, YY; Chang, KC; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, YH; Shao, SC | 1 |
Broedl Md, UC; Coleman, RL; Fitchett, D; George, JT; Gray, AM; Holman, RR; Woerle, HJ; Zinman, B | 1 |
Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B; Zwiener, I | 1 |
Ghosal, S; Sinha, B | 1 |
Fonseca, VA; Shao, H; Shi, L | 1 |
Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P; Wintzell, V | 1 |
Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A | 1 |
Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 1 |
Fitchett, DH; George, JT; Inzucchi, SE; Khunti, K; Mattheus, M; Ofstad, AP; Wanner, C; Zinman, B | 1 |
Higashi, Y; Hisauchi, I; Machii, N; Matsuzawa, Y; Node, K; Okada, Y; Shima, KR; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamaoka-Tojo, M | 1 |
Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Kooy, A; Langkilde, AM; Leiter, LA; Litwak, L; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I | 1 |
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J | 1 |
Asseburg, C; Brennan, A; Clarke, PM; Feenstra, T; Gray, A; Herman, WH; Isaman, DJ; Kuo, S; Lamotte, M; Leal, J; McEwan, P; Nilsson, A; Palmer, AJ; Patel, R; Pollard, D; Ramos, M; Sailer, F; Schramm, W; Shao, H; Shi, L; Si, L; Smolen, HJ; Tew, M; Willis, MS; Ye, W; Zhang, P | 1 |
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC | 1 |
Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD | 1 |
Eliasson, B; Inzucchi, SE; Johansen, OE; Kasai, T; Marx, N; Neeland, IJ; Wanner, C; Wojeck, BS; Yaggi, HK; Zinman, B; Zwiener, I | 1 |
Agarwala, A; Al Rifai, M; Hussain, A; Jia, X; Martin, S; Virani, SS | 1 |
Hui, Y; Xu, Y; Yang, C; Yin, D | 1 |
Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
Ceriello, A; George, J; Kaspers, S; Nicolucci, A; Ofstad, AP; Zwiener, I | 1 |
Khong, TK; Magavern, E | 1 |
Haynes, R; Judge, PK | 1 |
Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F | 1 |
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Held, C; Hou, FF; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
Aroda, VR; Sabatine, MS | 1 |
Khunti, K | 1 |
Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ | 1 |
Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
Tuttle, KR | 1 |
Nabavizadeh, P; Steen, DL | 1 |
Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K | 1 |
Hirose, T; Hiruma, S; Hisatake, S; Hori, M; Ikeda, T; Kumashiro, N; Mizumura, S; Shigiyama, F; Shiraga, N | 1 |
Cessario, J; Li, Z; Pierre-Louis, V; Wahl, J | 1 |
Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
Diogo, V; Gourzoulidis, G; Ioannidis, I; Karpouzos, G; Kourlaba, G; Papageorgiou, G; Tsimihodimos, V; Tzanetakos, C | 1 |
Li, N; Li, SY; Tian, HM; Wang, MY; Zhang, R; Zhang, YG; Zhou, YL | 1 |
Ferreira, JP; Fitchett, DH; George, JT; Koitka-Weber, A; Kraus, BJ; Lauer, S; Ofstad, AP; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
Ali, S; Brojen Singh, RK; Lebeche, D; Mangangcha, IR | 1 |
Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Kosiborod, M; Kurlyandskaya, R; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC | 1 |
Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
Brand, SB; Cragin, L; Fahrbach, K; Gandhi, PK; Kansal, AR; Pfarr, E; Reifsnider, OS; Ustyugova, A | 1 |
Chen, R; Fan, G; Wu, XY; Yi, H; Zhao, CC | 1 |
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D | 1 |
Booz, GW; Fan, F; Jiao, F; Liu, R; Liu, Y; Roman, RJ; Varghese, K; Wang, S; Yu, H | 1 |
Ang, L; Dillon, B; Fang, F; Kidwell, KM; Leone, V; Mizokami-Stout, K; Pop-Busui, R; Reiss, J | 1 |
Baggesen, LM; Holmgaard, PH; Kahlert, J; Knudsen, JS; Lajer, M; Sørensen, HT; Thomsen, RW; Ustyugova, A; Vedin, O | 1 |
Fitchett, D; George, J; Inzucchi, SE; Kosiborod, MN; Leiter, LA; Mattheus, M; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B | 1 |
Higashi, Y; Node, K; Okada, Y; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S | 2 |
Bajaj, HS; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Persson, F; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Wheeler, DC | 1 |
Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tasi, WC; Wu, BN | 1 |
Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H | 1 |
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure-Valenzuela, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Lam, CSP; Marx, N; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Schnaidt, S; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zeller, C; Zhang, J | 1 |
Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH | 1 |
Aschenbrenner, DS | 1 |
Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ | 1 |
Albers, GW; Broedl, UC; Diener, HC; Fitchett, D; Inzucchi, SE; Johansen, OE; Kohler, S; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Bain, S; Chudleigh, RA | 1 |
Avogaro, A; Bonora, E; Colivicchi, F; Ferrannini, E; Fioretto, P; Maggioni, AP; Perrone-Filardi, P; Sesti, G | 1 |
Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
Avogaro, A; Del Prato, S; Fioretto, P; Genovese, S; Giaccari, A; Giorgino, F; Purrello, F | 1 |
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
Palau, V; Riera, M; Soler, MJ | 1 |
Wanner, C | 2 |
Chilton, R | 1 |
Chilton, R; Pham, SV | 1 |
Staels, B | 2 |
Perreault, L | 2 |
Chen, KJ; Cong, WH; Guo, G; Hu, YJ; Lee, SM; Liao, QW; Wang, Y; Xin, QQ; Yang, BR | 1 |
Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
Burggraaf, B; Castro Cabezas, M | 1 |
Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M | 1 |
Chilton, RJ | 1 |
Chilton, RJ; Pham, SV | 1 |
Kaul, S | 1 |
Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S; Ryder, REJ; Singh, R | 1 |
Cherney, DZI; Inzucchi, SE; Koitka-Weber, A; Mattheus, M; von Eynatten, M; Wanner, C; Zinman, B | 1 |
Ernest, P; Jandrain, B; Scheen, AJ; Wallemacq, C | 1 |
Drexler, A | 1 |
Jabbour, S | 1 |
Gürke, L; Tampaki, EC; Tampakis, A | 2 |
Diener, HC; Inzucchi, SE; Zinman, B | 1 |
Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M | 2 |
Black, RL; Irons, BK; Minze, MG; Terrell, BT; Will, KJ | 1 |
Athyros, VG; Doumas, M; Imprialos, KP; Karagiannis, A; Stavropoulos, K | 1 |
Adamski, J; Artati, A; Kappel, BA; Lebherz, C; Lehrke, M; Marx, N; Schütt, K | 1 |
Jumar, A; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Schneider, MP; Striepe, K | 1 |
Chen, YQ; Deng, XJ; Li, D; Song, F; Ya, FL; Yang, Y; Zhang, XD; Zhou, FH | 1 |
Butler, J; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Bell, RM; Yellon, DM | 1 |
Al-Omran, M; Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Mazer, CD; Verma, S; Zinman, B | 1 |
Coleman, CI; Nair, S; Nguyen, E; Weeda, ER | 1 |
Bluhmki, E; Ferrannini, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Ohneberg, K; Schmoor, C; Schumacher, M; Wanner, C; Zinman, B | 1 |
Suissa, S | 1 |
Bakris, G; Plutzky, J | 1 |
Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD | 1 |
Broedl, UC; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Gourzoulidis, G; Ioannidis, I; Kourlaba, G; Maniadakis, N; Papageorgiou, G; Tsapas, A; Tzanetakos, C | 1 |
Paquot, N; Scheen, AJ | 1 |
Eckel, RH; Koh, KK; Lim, S | 1 |
Chang, J; Goyat, R; Ponte, CD; Rai, P; Tan, X | 1 |
Bell, KF; Enhoffer, DM; Eudicone, JM; Green, JB; Latham, K; Wittbrodt, ET | 1 |
Duong, J; Herman, WH; Kuo, S; Ye, W | 1 |
Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Kosiborod, M | 1 |
Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B | 1 |
Leiter, LA; Lingvay, I | 1 |
Ren, DY; Zhang, Y | 1 |
Akiyama, N; Kashiwagi, A; Kazuta, K; Kosakai, Y; Nakamura, I; Sakatani, T; Takahashi, H; Ueyama, E | 1 |
Fuchigami, A; Hirose, T; Kumashiro, N; Shigiyama, F | 1 |
Frampton, JE | 1 |
De Ponti, F; Fadini, GP; Marchesini, G; Poluzzi, E; Raschi, E | 1 |
Arbel, R; Azuri, J; Hammerman, A | 1 |
Inzucchi, SE; Lupsa, BC | 1 |
Marx, N; Wanner, C | 1 |
Goldman, JD | 1 |
Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
Claggett, B; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Lachin, JM; Woerle, HJ; Zinman, B | 1 |
Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Kaspers, S; Kosiborod, M; Wanner, C; Zinman, B | 1 |
Koh, KK | 1 |
von Eynatten, M; Wanner, C; Zinman, B | 1 |
Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C | 1 |
Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
Dong, P; Liu, H; Zhao, D | 1 |
Bookhart, B; Cai, J; Durkin, M; Kamstra, R; Lafeuille, MH; Lefebvre, P; Manceur, AM; Pilon, D; Tiggelaar, S | 1 |
Bodegård, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M | 2 |
Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J | 1 |
Abdul Rashid, AM; Adams, L; Agah, R; Ahmad Saad, FF; Akay, S; Appiah-Opong, R; Aronson, RD; Asbun, H; Ashong, Y; Ayi, I; Baez, P; Bar-Ad, V; Bay, JL; Bello-Pagan, M; Blackbourn, LAK; Bolan, C; Brierley, L; Cannaday, S; Cannon, TL; Caparrotta, TM; Capitano, M; Colhoun, HM; Coppola, D; Crees, ZD; Crites, D; Devaraj, K; Dumashie, E; Edil, BH; Endo, K; Ferrone, CR; Forcione, DG; Ford, J; Fortuna, D; Garcia, M; Gilad, GM; Gomez, V; Gonzalez, C; Gwira, TM; Han, JY; Hanaki, T; Hardacre, JM; Hester, D; Hidalgo, M; Hirschler, V; Hodul, PJ; Ikeguchi, M; Intersimone, P; Jang, JH; Ji, Z; Johnson, T; Kandel, P; Koh, R; Lee, G; Lee, IG; Leese, GP; Li, J; Liu, X; Lopez, MJ; Maccallini, G; Macdonald, DB; Malek, R; Maley, WR; Martel, G; McCrimmon, RJ; McGurnaghan, SJ; McKeigue, PM; McKnight, JA; Md Noh, MSF; Miao, Y; Mody, K; Molinari, C; Monroe, JF; Mora, HA; Morton, SM; Moyana, TN; Munoz-Jordan, J; Nakamura, S; Neaterour, P; Orcutt, ST; Palmer, JD; Paniccia, A; Park, J; Pearson, ER; Perez, NP; Petrie, JR; Pyatibrat, S; Rademacher, N; Raimondo, M; Ranasinha, N; Reyes, N; Richardson, LC; Ritter, AW; Rivera, A; Rivera-Garcia, B; Rosemurgy, AS; Ross, SB; Sama, A; Sattar, N; Sawata, T; Schulick, RD; Shang, D; Sharp, TM; Shimizu, T; Şirin, B; Sloboda, DM; So, E; Song, X; Srour, SA; Stauffer, J; Suzuki, K; Taguchi, T; Takawira, C; Torphy, R; Trump, DL; Tuffour, I; Ünsal, B; Van Dyne, EA; Vickers, MH; Vitulli, PL; Wallace, MB; Wang-Gillam, A; Waterman, SH; Wei, J; Weinstein, JC; Wild, SH; Williams, N; Winter, J; Woodward, TA; Wu, ES; Wu, J; Yeo, CJ; Yeo, TP; Yeung, V; Zhang, JB | 1 |
Aharon-Hananel, G; Raz, I | 1 |
Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T | 1 |
Kaneko, M; Narukawa, M | 1 |
Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
De Ponti, F; Marchesini, G; Poluzzi, E; Raschi, E | 1 |
Scheen, AJ | 6 |
Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS | 1 |
Aliani, M; Austria, JA; Maddaford, TG; Netticadan, T; Parikh, M; Pierce, GN | 1 |
Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 1 |
Davis, SN; Hedrington, M; Lamos, EM | 1 |
Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
Rothenberg, F; Schacht, S; Thompson, J | 1 |
Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
Anthony, S; Bajwa, H; Peter, R | 1 |
Horng, LY; Hsu, PL; Peng, KY; Sung, HC; Wu, CL; Wu, RT | 1 |
Hardy, E; Johnsson, E; List, J; Parikh, S; Ptaszynska, A | 1 |
de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Stein, P; Vercruysse, F | 1 |
Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 1 |
Bluhmki, E; Broedl, UC; Ferrari, R; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Kempthorne-Rawson, J; Lachin, JM; Newman, J; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Bennett, H; Bergenheim, K; McEwan, P; Ward, T | 1 |
Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K | 1 |
Heneghan, CJ; Onakpoya, IJ | 1 |
Andrenacci, E; Biscaglia, S; Campo, G; Ferrari, R; Ferri, A; Pavasini, R; Tebaldi, M | 1 |
Alameddine, A; Ayer, A; Bourreau, J; Custaud, MA; Derbre, S; Fajloun, Z; Gauguier, D; Gauquelin-Koch, G; Navasiolava, N; Yuan, M | 1 |
Bluhmki, E; Broedl, UC; Devins, T; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, E; van Bommel, EJ; van Raalte, DH | 1 |
Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 1 |
Connelly, KA; Gilbert, RE | 1 |
Basu, S; Naci, H; Yudkin, JS | 1 |
Ingelfinger, JR; Rosen, CJ | 2 |
Malhotra, S; Shafiq, N | 1 |
McGuire, DK; Neeland, IJ; Salahuddin, U | 1 |
Overbeck, P | 1 |
Shekelle, P | 1 |
Gause-Nilsson, I; Johansson, PA; Johnsson, E; Sonesson, C | 1 |
Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE | 1 |
Maltezos, ES; Papanas, N; Tsioufis, C | 1 |
Ebell, MH | 1 |
Einecke, D | 1 |
Zechmann, S | 1 |
Inzucchi, SE; Lachin, JM; Zinman, B | 1 |
Sarafidis, PA; Tsapas, A | 1 |
Edwards, JL | 1 |
Fischereder, M; Schönermarck, U | 1 |
Hough, A; Rosenstein, R | 1 |
Müller-Wieland, D | 1 |
Bloomgarden, Z | 1 |
Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH | 1 |
Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
Bandyopadhyay, D; Biswas, M; Ghosh, RK; Gupta, A; Hajra, A | 1 |
Kawai, T; Meguro, S; Sano, M; Suzuki, Y | 1 |
Mellbin, L; Rydén, L; Shahim, B | 1 |
Kristensen, SL; McLaren, J; McMurray, JJ; Preiss, D; Sattar, N | 1 |
Stiefelhagen, P | 1 |
Gupta, Y; Kalra, S; Kishor, K | 1 |
Bondonno, CP; Bondonno, NP; Croft, KD; Hodgson, JM; Mas, E; Rich, L; Shinde, S; Ward, NC | 1 |
Laubner, K; Seufert, J | 1 |
Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S | 1 |
Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH | 1 |
Perseghin, G; Solini, A | 1 |
Arnheim, K | 1 |
Alloju, S; Henry, RR; Mudaliar, S | 1 |
Ferrannini, E; Mark, M; Mayoux, E | 1 |
Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y | 1 |
Bonadonna, RC; Borghi, C; Consoli, A; Volpe, M | 1 |
Broedl, UC; Hantel, S; Kim, G; Salsali, A; Woerle, HJ | 1 |
Preiss, D; Sattar, N | 1 |
Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A | 1 |
Dicembrini, I; Mannucci, E; Monami, M | 1 |
Grant, PJ | 1 |
Hernández, C; Simó, R | 1 |
Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, EJ; van Raalte, DH | 1 |
Dalama, B; Mesa, J | 1 |
Khandelwal, S; Naing, S; Poliyedath, A; Sigala, T | 1 |
Di Franco, A; Luconi, M; Mannucci, E; Raimondi, L | 1 |
Cusi, K | 1 |
Inzucchi, SE; Stamatouli, AM | 1 |
Rossello, X; Yellon, DM | 1 |
Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
Boutari, C; Doumas, M; Imprialos, KP; Karagiannis, AI; Stavropoulos, K | 1 |
George, J; Kaku, K; Kaspers, S; Lee, J; Mattheus, M; Woerle, HJ | 1 |
Koya, D | 1 |
Node, K; Tanaka, A | 1 |
Rajput, R; Ved, J | 1 |
Fioretto, P; Inzucchi, SE; Vettor, R | 1 |
Nuffer, WA; Trujillo, JM | 1 |
Lazaridis, AA; Ruilope, LM; Ruiz-Hurtado, G; Sarafidis, PA | 1 |
Bando, YK; Murohara, T | 1 |
Fiorentino, TV; Sesti, G | 1 |
Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
Turner, JR | 1 |
Avogaro, A; Fioretto, P | 1 |
Alzaid, A | 1 |
Adolphe, JL; Alcorn, J; Juurlink, BH; Thorpe, LU; Whiting, SJ | 1 |
Wick, JY | 1 |
Andrews, MC; Chen, P; Jin, JW; Li, C; Ling, W; Ni, H; Reheman, A; Shi, Z; Wang, Y; Yang, Y; Zhu, G | 1 |
de BUMAN, M | 1 |
Gibbins, JM; Hubbard, GP; Lovegrove, JA; Wolffram, S | 1 |
Samilova, RD | 1 |
Hollman, PC; Katan, MB; Olthof, MR; Zock, PL | 1 |
Reviews
79 review(s) available for glucose, (beta-d)-isomer and Cardiovascular Diseases
Article | Year |
---|---|
Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.
Topics: Animals; Anticholesteremic Agents; Biological Products; Cardiovascular Diseases; Dietary Supplements; Humans; Hypercholesterolemia; Risk Factors; Zymosan | 2017 |
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Diseases; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
Topics: Benzhydryl Compounds; Betacoronavirus; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Congresses as Topic; Coronavirus Infections; COVID-19; Eicosapentaenoic Acid; Europe; Glucosides; Humans; Lipid Regulating Agents; Oligonucleotides; Pandemics; Pneumonia, Viral; SARS-CoV-2; Societies, Medical; Telecommunications | 2020 |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The Therapeutic Effects and Mechanisms of Salidroside on Cardiovascular and Metabolic Diseases: An Updated Review.
Topics: Animals; Cardiovascular Diseases; Glucosides; Humans; Metabolic Diseases; Phenols | 2021 |
Recent Insights Into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drugs, Chinese Herbal; Glucosides; Humans; Kidney Diseases; Monoterpenes; Nervous System Diseases | 2021 |
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome | 2016 |
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic | 2017 |
Mechanisms linking empagliflozin to cardiovascular and renal protection.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Consensus; Delphi Technique; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Life Style; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Risk; United States; United States Food and Drug Administration | 2018 |
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Hospitalization; Humans; Kidney; Protective Agents; Renal Elimination; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Empagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Observational Studies as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide | 2018 |
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Weight Loss | 2019 |
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Survival Rate | 2019 |
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Dietary Flaxseed as a Strategy for Improving Human Health.
Topics: alpha-Linolenic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Butylene Glycols; Cardiovascular Diseases; Diet; Dietary Fiber; Dietary Supplements; Fatty Acids, Omega-3; Female; Flax; Functional Food; Gastrointestinal Diseases; Glucosides; Hormones; Humans; Lignans; Lipid Metabolism; Neoplasms; Seeds | 2019 |
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Patient Selection; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Effects of dapagliflozin on cardiovascular risk factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transport Proteins | 2013 |
Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials.
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Dietary Supplements; Diterpenes, Kaurane; Glucosides; Humans; Hypertension; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sweetening Agents | 2015 |
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Topics: Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
SGLT2 inhibitors: new reports.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Research Report; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
Topics: Adult; Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transport Proteins; Treatment Outcome | 2016 |
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Global Health; Glucosides; Humans; Hypoglycemic Agents; Survival Rate | 2016 |
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Glucosides; Heart Rate; Humans; Hypoglycemic Agents; Metformin; Obesity; Phenotype | 2016 |
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss | 2016 |
The EMPA-REG outcome study: critical appraisal and potential clinical implications.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care; Risk Factors | 2016 |
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Treatment Outcome | 2016 |
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Incretins; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
Topics: Aged; Benzhydryl Compounds; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk Factors | 2016 |
Research digest.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2016 |
Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2016 |
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Impact of EMPA-REG OUTCOME
Topics: Benzhydryl Compounds; Body Weights and Measures; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Randomized Controlled Trials as Topic; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Myocytes, Cardiac; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2016 |
Implications of the EMPA-REG Trial for Clinical Care and Research.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Topics: Benzhydryl Compounds; Blood Viscosity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Stroke | 2017 |
Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 1 | 2017 |
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reference Values; Treatment Outcome | 2017 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.
Topics: Adult; Animals; Antineoplastic Agents; Benzhydryl Compounds; Blood Pressure; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Hypoglycemic Agents | 2017 |
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Health effects with consumption of the flax lignan secoisolariciresinol diglucoside.
Topics: Animals; Antioxidants; Butylene Glycols; Cardiovascular Diseases; Diabetes Mellitus; Diet; Enzyme Activators; Enzyme Inhibitors; Female; Flax; Glucosides; Humans; Lignin; Neoplasms; Phytoestrogens; Pregnancy | 2010 |
Aspirin: a history, a love story.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzyl Alcohols; Cardiovascular Diseases; Drug Hypersensitivity; Drug Resistance; Glucosides; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Neoplasms; Salix; Sex Characteristics | 2012 |
Trials
83 trial(s) available for glucose, (beta-d)-isomer and Cardiovascular Diseases
Article | Year |
---|---|
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Treatment Outcome; Uric Acid | 2022 |
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States | 2022 |
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Treatment Outcome | 2022 |
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hemodynamics; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Flow Velocity; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Echocardiography, Doppler; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2022 |
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Nephrolithiasis; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Calculi | 2022 |
Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucose; Glucosides; Humans; Hypoglycemic Agents; RNA, Ribosomal, 16S | 2022 |
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Isoprostanes; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Treatment Outcome | 2022 |
Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiography, Impedance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart; Hemodynamics; Humans; Italy; Male; Middle Aged; Predictive Value of Tests; Single-Blind Method; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans; Middle Aged; Myeloid Progenitor Cells; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Prognosis; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke | 2019 |
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Denmark; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney | 2020 |
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss | 2020 |
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors | 2020 |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Risk Factors; Thrombolytic Therapy | 2020 |
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2020 |
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial func
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Brain Ischemia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Stroke; Treatment Outcome | 2021 |
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Incidence; Kidney Diseases; Male; Middle Aged; Prevalence; Risk Factors; Sleep; Sleep Apnea, Obstructive; Treatment Outcome | 2020 |
Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic | 2021 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Pilot Projects; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure | 2021 |
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Topics: Adiposity; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Metabolism; Female; Glucosides; Glycated Hemoglobin; Heart; Humans; Male; Middle Aged; Myocardium; Primary Prevention; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tokyo; Treatment Outcome | 2021 |
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2021 |
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Prospective Studies; Treatment Outcome | 2021 |
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluid Shifts; Glucosides; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Water-Electrolyte Balance | 2021 |
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Japan; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss | 2017 |
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Outcome Assessment, Health Care; Risk; Stroke | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors | 2017 |
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Germany; Glucosides; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Young Adult | 2017 |
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Peripheral Arterial Disease; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk Factors; Treatment Outcome | 2018 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Mortality; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome | 2018 |
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Male; Middle Aged; Risk Factors; Thiophenes; Treatment Outcome | 2018 |
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Japan; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2 | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; Drug Administration Schedule; Female; Glucosides; Hormones; Humans; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Treatment Outcome; Young Adult | 2019 |
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Analysis from the EMPA-REG OUTCOME
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Time Factors | 2014 |
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Research Design; Treatment Outcome; Young Adult | 2014 |
Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study.
Topics: Adenosine Diphosphate; Aged; Capsules; Cardiovascular Diseases; Chemistry, Pharmaceutical; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Phenols; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Treatment Outcome | 2015 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors | 2015 |
[Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Combined Modality Therapy; Diabetic Angiopathies; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate | 2015 |
[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2015 |
Acute effects of quercetin-3-O-glucoside on endothelial function and blood pressure: a randomized dose-response study.
Topics: Aged; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Cross-Over Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Flavonoids; Glucosides; Humans; Male; Middle Aged; Nitric Oxide; Plant Extracts; Quercetin; Reference Values; Vasodilation | 2016 |
[Effect of dapagliflozin on cardiovascular risk factors].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrolytes; Endpoint Determination; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome | 2016 |
[Empagliflozin also protects high risk patients].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Humans; Risk Factors; Survival Rate | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors | 2016 |
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
Topics: Aged; Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome | 2017 |
Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans.
Topics: Blood Platelets; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Collagen; Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Female; Flavonols; Glucosides; Humans; Immunoblotting; Male; Phosphorylation; Platelet Activation; Platelet Aggregation; Quercetin; Signal Transduction; Thrombosis; Time Factors; Tyrosine | 2004 |
Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans.
Topics: Adult; Cardiovascular Diseases; Chlorogenic Acid; Coffee; Cross-Over Studies; Fasting; Female; Flavonoids; Folic Acid; Glucosides; Homocysteine; Humans; Male; Phenols; Polymers; Postprandial Period; Pyridoxine; Quercetin; Risk Factors; Tea; Vitamin B 12 | 2001 |
Other Studies
152 other study(ies) available for glucose, (beta-d)-isomer and Cardiovascular Diseases
Article | Year |
---|---|
Role of nitric oxide in a nonseptic shock model induced by zymosan in the rat.
Topics: Acute Disease; Animals; Ascitic Fluid; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibitors; Male; Nitrates; Nitric Oxide; Nitrites; Peritonitis; Rats; Rats, Sprague-Dawley; Shock; Vasomotor System; Zymosan | 1997 |
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Medicare; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2022 |
[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycemic Control; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hematocrit; Humans; Risk Factors | 2022 |
A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Nutrition Surveys; Pregnancy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; United States | 2022 |
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2022 |
Pharmacological analysis of Empagliflozin: Acting through the CaMKII pathway in type 2 diabetes and acute cardiovascular events.
Topics: Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation | 2022 |
Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Heart Ventricles; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2022 |
Healthberry 865
Topics: Animals; Anthocyanins; Cardiovascular Diseases; Endothelial Cells; Glucosides; Humans; Oxidative Stress | 2022 |
Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Economic | 2022 |
Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chitosan; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Pharmaceutical Preparations | 2022 |
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; COVID-19; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Morbidity; Pandemics; Prospective Studies; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome; Vascular Stiffness | 2022 |
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; South Africa | 2023 |
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic | 2023 |
Diosmetin-7-O-β-D-glucopyranoside suppresses endothelial-mesenchymal transformation through endoplasmic reticulum stress in cardiac fibrosis.
Topics: Animals; Cardiomyopathies; Cardiovascular Diseases; Collagen; Endoplasmic Reticulum Stress; Endothelial Cells; Epithelial-Mesenchymal Transition; Fibrosis; Flavonoids; Glucosides; Mice; Molecular Docking Simulation | 2023 |
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Global Health; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome | 2019 |
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Decision-Making; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Hospitalization; Humans; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protective Factors; Research Design; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2019 |
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
SGLT2 inhibitors for primary prevention of cardiovascular events.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Prevention; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eligibility Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Reproducibility of Results; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2019 |
Dapagliflozin Cut Risk of Worsening Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Topics: Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Glucose; Glucosides; Humans; Lipid Metabolism; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Observational Studies as Topic; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Prognosis; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Norway; Proportional Hazards Models; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2020 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2020 |
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome | 2020 |
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin (Farxiga) - a new indication for heart failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Economic; Outcome Assessment, Health Care; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors | 2020 |
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2021 |
Highlights from the European society of cardiology congress 2020.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Coronary Artery Disease; Europe; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors; Tubulin Modulators; Uracil | 2021 |
Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cell Death; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years | 2021 |
Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tertiary Care Centers | 2021 |
Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
Topics: Androgen Antagonists; Androgens; Cardiovascular Diseases; Glucosides; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Molecular Docking Simulation; Phosphates; Prostatic Neoplasms; Protein Isoforms; Serine; Xanthones | 2022 |
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Standard of Care | 2021 |
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Qatar | 2022 |
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Topics: Acute Disease; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Population Surveillance; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome | 2021 |
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Male | 2021 |
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Connexin 43; Connexins; Diet, High-Fat; Disease Models, Animal; Echocardiography; Electrocardiography; Gene Expression Regulation; Glucose; Glucosides; Glyburide; Humans; Metabolic Syndrome; Mice; Sodium-Glucose Transporter 2 | 2021 |
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left | 2017 |
Diabetes Drug Receives New Indication.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Labeling; Drug Repositioning; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
Topics: Albuminuria; Anti-Inflammatory Agents; Benzhydryl Compounds; Cardiovascular Diseases; Cytokines; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Heart; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Oxidative Stress; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels.
Topics: Animals; Cardiovascular Diseases; Drug Synergism; Drugs, Chinese Herbal; Embryo, Nonmammalian; Estrogen Receptor alpha; Gene Expression Regulation; Glucosides; Ligands; Monoterpenes; Neovascularization, Physiologic; Pyrazines; Reproducibility of Results; Zebrafish | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Treatment Outcome | 2017 |
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Can we go beyond surrogates?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors | 2017 |
Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors | 2017 |
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden | 2018 |
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Male; Metabolomics; Middle Aged; Myocardium; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Anthocyanin Cyanidin-3-Glucoside Attenuates Platelet Granule Release in Mice Fed High-Fat Diets.
Topics: Animals; Anthocyanins; beta-Thromboglobulin; Blood Platelets; Cardiovascular Diseases; Chemokine CCL5; Diet; Diet, High-Fat; Dietary Supplements; Glucosides; Lipids; Male; Mice; Mice, Inbred C57BL; Platelet Activation; Platelet Factor 4; Secretory Vesicles; Serotonin; Transforming Growth Factor beta1 | 2017 |
SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Costs; Female; Glucosides; Humans; Male; Middle Aged; Morbidity; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome | 2018 |
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Topics: Benzhydryl Compounds; Bias; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Mortality; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium | 2018 |
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome | 2018 |
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Treatment Outcome | 2018 |
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2018 |
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Renal Insufficiency, Chronic | 2018 |
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Costs; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Antihyperglycemic medications for cardiovascular disease risk reduction.
Topics: Benzhydryl Compounds; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2018 |
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Female; Glucosides; Humans; Life Expectancy; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Health Expenditures; Humans; Hypoglycemic Agents; Models, Economic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Research Design; Sweden; Treatment Outcome | 2019 |
Topics: Adult; Aged; Animals; Antigens, Helminth; Apoptosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Carcinogenesis; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cell Proliferation; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Endosonography; Feces; Female; Glomerular Filtration Rate; Glucosides; Glutathione; Humans; Logistic Models; Male; Middle Aged; Ovum; Oxidative Stress; Pancreas; Pancreatic Elastase; Pancreatitis, Chronic; Patient Safety; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Prospective Studies; Prostate; Risk Factors; Schistosoma; Schistosomiasis; Scotland; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Systole; Treatment Outcome | 2017 |
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemia; Ketosis; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.
Topics: Animals; Cardiovascular Diseases; Cell Line; Cells, Cultured; Cisplatin; Doxorubicin; Erythropoietin; Glucosides; HEK293 Cells; Hemoglobins; Hepatocytes; Humans; Kidney; Male; Mice; Mice, Inbred C57BL; Mitochondria; Myocytes, Cardiac; Receptors, Erythropoietin; Stilbenes | 2013 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom | 2015 |
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model.
Topics: Animals; Aorta; Blood Pressure; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose Intolerance; Glucosides; Guanylate Cyclase; Heart Rate; Hyperglycemia; Hypertension; Male; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Phenols; Rats; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation | 2015 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Preventing cardiovascular events with empagliflozin: at what cost?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Superiority trials: statistical trickery or mass blindness?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2015 |
ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
[Empagliflozin reduces heart failure risk by a third].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Heart Failure; Humans; Outcome Assessment, Health Care; Risk; Survival Rate | 2015 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
[Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Glycemic control and the heart: it matters how you get there.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Outcome Assessment, Health Care; Pioglitazone; Thiazolidinediones | 2016 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Increased grip strength with sodium-glucose cotransporter 2.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[The cardiovascular outcome is critical].
Topics: Benzhydryl Compounds; Biosimilar Pharmaceuticals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine | 2016 |
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Energy Metabolism; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male | 2016 |
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections | 2016 |
SGLT2 Inhibitors and the Diabetic Kidney.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
London buses: A cardiovascular outcome trial equivalent?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Protective Factors; Risk Factors; Treatment Outcome | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
Renoprotection in LEADER and EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2016 |
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2016 |
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2017 |
Obesity Week 2016 Annual Meeting.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss | 2017 |
Impact of empagliflozin on diabetic kidney disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Reverse causality in Empa-Reg Outcome: The proverbial elephant?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Causality; Diabetes Mellitus, Type 2; Elephants; Glucosides; Humans; Hypoglycemic Agents; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2; Treatment Outcome | 2017 |
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Asian Perspective of the EMPA-REG OUTCOME Study.
Topics: Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care | 2017 |
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Registries; Risk Factors; Sweden | 2017 |
[Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors | 2016 |
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans | 2017 |
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Approval; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Mortality; Multicenter Studies as Topic; Survival Analysis | 2017 |
Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases.
Topics: AMP-Activated Protein Kinases; Analysis of Variance; Animals; Anthocyanins; Bleeding Time; Cardiovascular Diseases; CD40 Ligand; Flow Cytometry; Gene Expression Regulation; Glucosides; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; P-Selectin; Phosphorylation; Platelet Activation; Tetraspanin 30; Thrombosis | 2012 |
[Treatment of cardiac patients with cardipyrine Hommel].
Topics: Cardiovascular Diseases; Digitalis; Digitalis Glycosides; Glucosides; Humans; Plant Extracts | 1950 |
[Effect of olitoriside and vitamin B12 on the content of adenylic nucleotides in the myocardium in acute cardiovascular insufficiency].
Topics: Adenine Nucleotides; Animals; Cardenolides; Cardiac Glycosides; Cardiovascular Diseases; Drug Therapy, Combination; Female; Glucosides; Glycosides; Male; Myocardium; Rats; Vitamin B 12 | 1981 |